September 24, 2024
Metsera’s Long-Acting GLP-1 Drug Shows Promising 7.5% Weight Loss in 36 Days, Paving Way for Monthly Dosing
Metsera, GLP-1, obesity treatment, long-acting drug, weight loss, monthly dosing, MET-097, clinical trial results.
Bristol Myers Squibb Continues Layoffs in New Jersey, Cutting 79 More Jobs
Bristol Myers Squibb, BMS layoffs, New Jersey layoffs, pharmaceutical industry layoffs, cost-savings measures
AI Guidance for Investors: Navigating the Future with Strategic Approaches and Regulatory Insights
AI Guidance for Investors, Strategic AI Adoption, Regulatory Impact on AI, Cybersecurity Risks in AI, AI Mapping Strategies, Data Governance in AI, Future of AI in Healthcare
Biohaven Achieves Breakthrough in Spinocerebellar Ataxia Treatment with Positive Pivotal Study Results for Troriluzole
Biohaven, Troriluzole, Spinocerebellar Ataxia (SCA), Pivotal Study Results, Neurodegenerative Disease, FDA Submission, New Drug Application (NDA)
Biohaven Revives Troriluzole Hopes with Positive Update for Spinocerebellar Ataxia
Troriluzole, Spinocerebellar Ataxia (SCA), Biohaven Pharmaceuticals, Neurodegenerative Disorders, FDA New Drug Application (NDA), Clinical Trials, Rare Diseases
Telix Acquires RLS to Bolster Radiopharmaceutical Manufacturing and Distribution in North America
Telix Pharmaceuticals, RLS (USA) Inc., radiopharmaceutical manufacturing, distribution, acquisition, North America, radiometal production network
FDA Approves Bimzelx for Expanded Indications: Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Bimzelx, FDA approval, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A and IL-17F inhibitor
Vicebio Secures $100 Million Funding to Advance Multivalent Respiratory Virus Vaccines
Vicebio, Multivalent Respiratory Virus Vaccines, $100 Million Funding, Series B Funding Round, Molecular Clamp Technology, RSV and hMPV Vaccine Combo